Department of Spine Surgery, The Third Affiliated Hospital, Sun Yat-sen University, No.600 Tianhe Road, Tianhe District, Guangzhou, 510630, Guangdong, China.
Guangdong Provincial Center for Quality Control of Minimally Invasive Spine Surgery, No. 600 Tianhe Road, Guangzhou, 510630, China.
Stem Cell Res Ther. 2020 Jul 10;11(1):276. doi: 10.1186/s13287-020-01781-w.
This study aimed to investigate the effect of bone marrow mesenchymal stem cell (BMSC)-derived exosome injection on cartilage damage and pain relief in both in vitro and in vivo models of osteoarthritis (OA).
The BMSCs were extracted from rat bone marrow of the femur and tibia. Chondrocytes were treated with IL-1β to establish the in vitro model of OA. Chondrocyte proliferation and migration were assessed by CCK-8 and transwell assay, respectively. A rat model of OA was established by injection of sodium iodoacetate. At 6 weeks after the model was established, the knee joint specimens and dorsal root ganglion (DRG) of rats were collected for histologic analyses. For pain assessment, paw withdrawal threshold (PWT) and paw withdrawal latency (PWL) were evaluated before model establishment and at 1, 2, 4, and 6 weeks after model establishment.
Exosomes can be endocytosed with the chondrocytes in vitro. Exosome treatment significantly attenuated the inhibitory effect of IL-1β on the proliferation and migration of chondrocytes. Exosome pre-treatment significantly attenuated IL-1β-induced downregulation of COL2A1 and ACAN and upregulation of MMP13 and ADAMTS5. In the animal study, exosome treatment significantly upregulated COL2A1 protein and downregulated MMP13 protein in the cartilage tissue of the OA rat. At weeks 2, 4, and 6, the PWL value was significantly improved in the exosome-treated OA rats as compared with the untreated OA animals. Moreover, exosome treatment significantly alleviated the upregulation of CGRP and iNOS in the DRG tissue of OA rats.
BMSC-derived exosomes can effectively promote cartilage repair and extracellular matrix synthesis, as well as alleviate knee pain in the OA rats.
本研究旨在探讨骨髓间充质干细胞(BMSC)衍生的外泌体注射对体外和体内骨关节炎(OA)模型中软骨损伤和缓解疼痛的影响。
从大鼠股骨和胫骨骨髓中提取 BMSCs。用白细胞介素 1β(IL-1β)处理软骨细胞,建立体外 OA 模型。分别通过 CCK-8 和 Transwell 测定评估软骨细胞的增殖和迁移。通过注射碘乙酸钠建立大鼠 OA 模型。在模型建立 6 周后,收集大鼠膝关节标本和背根神经节(DRG)进行组织学分析。为了评估疼痛,在模型建立前和建立后 1、2、4 和 6 周时评估足爪撤回阈值(PWT)和足爪撤回潜伏期(PWL)。
外泌体可被体外软骨细胞内吞。外泌体处理显著减弱了 IL-1β对软骨细胞增殖和迁移的抑制作用。外泌体预处理显著减弱了 IL-1β诱导的 COL2A1 和 ACAN 下调以及 MMP13 和 ADAMTS5 上调。在动物研究中,外泌体处理显著上调了 OA 大鼠软骨组织中的 COL2A1 蛋白,下调了 MMP13 蛋白。与未治疗的 OA 动物相比,在治疗后的第 2、4 和 6 周,OA 大鼠的 PWL 值显著提高。此外,外泌体治疗显著减轻了 OA 大鼠 DRG 组织中 CGRP 和 iNOS 的上调。
BMSC 衍生的外泌体可有效促进软骨修复和细胞外基质合成,并缓解 OA 大鼠的膝关节疼痛。